# Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects

> **NCT02808455** · PHASE1 · COMPLETED · sponsor: **CTI BioPharma** · enrollment: 12 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** (Treatment A)
- **DRUG:** (Treatment B)

## Key facts

- **NCT ID:** NCT02808455
- **Lead sponsor:** CTI BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-01
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-09-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02808455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02808455, "Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02808455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*